GTCM
RCUS icon

Gyon Technologies Capital Management’s Arcus Biosciences RCUS Stock Holding History

Gyon Technologies Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,990
Closed -$351K – 323
2022
Q4 		$351K Sell
16,990
-9,572
-36% -$263K 0.13% 167
2022
Q3 		$695K Buy
+26,562
New +$702K 0.22% 120

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gyon Technologies Capital Management's RCUS Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 16,990 shares — an estimated $351K sold.

Gyon Technologies Capital Management first reported a position in RCUS in Q3 2022 and held it in 2 quarters. The position peaked at $695K in Q3 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 16,990 Arcus Biosciences shares in Q1 2023, an estimated $351K.
  • Gyon Technologies Capital Management first reported a position in Arcus Biosciences in Q3 2022 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Arcus Biosciences position peaked at $695K in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.